Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Daily Cisplatin and Weekly Docetaxel Versus Weekly Cisplatin Intra-Arterial Chemoradiotherapy for Late T2-3 Tongue Cancer: A Pilot and Feasibility Trial

Yuichiro Hayashi
* ORCID logo ,
Shuhei Minamiyama
,
Takashi Ohya
,
Masaki Iida
,
Toshinori Iwai
,
Toshiyuki Koizumi
,
Senri Oguri
,
Makoto Hirota
,
Mitomu Kioi
,
Masaharu Hata
,
Masataka Taguri
,
Kenji Mitsudo
Version 1 : Received: 5 May 2018 / Approved: 7 May 2018 / Online: 7 May 2018 (08:48:20 CEST)

A peer-reviewed article of this Preprint also exists.

Hayashi, Y.; Minamiyama, S.; Ohya, T.; Iida, M.; Iwai, T.; Koizumi, T.; Oguri, S.; Hirota, M.; Kioi, M.; Hata, M.; Taguri, M.; Mitsudo, K. Daily Cisplatin and Weekly Docetaxel versus Weekly Cisplatin Intra-Arterial Chemoradiotherapy for Late T2-3 Tongue Cancer: A Pilot and Feasibility Trial. Medicina 2018, 54, 52. Hayashi, Y.; Minamiyama, S.; Ohya, T.; Iida, M.; Iwai, T.; Koizumi, T.; Oguri, S.; Hirota, M.; Kioi, M.; Hata, M.; Taguri, M.; Mitsudo, K. Daily Cisplatin and Weekly Docetaxel versus Weekly Cisplatin Intra-Arterial Chemoradiotherapy for Late T2-3 Tongue Cancer: A Pilot and Feasibility Trial. Medicina 2018, 54, 52.

Abstract

Purpose: The aim of present study was to compare the treatment results of daily cisplatin (CDDP), weekly docetaxel (DOC) intra-arterial infusion chemotherapy combined with radiotherapy (DIACRT) regimen and weekly CDDP intra-arterial infusion chemotherapy combined with radiotherapy (WIACRT) for patients with tongue cancer. Materials and Methods: Between January 2007 and December 2016, a total of 11 patients treated with WIACRT and 45 patients treated with DIACRT were enrolled in present study. In DIACRT group, 25 patients had T2, 20 patients had T3. A total of 9 patients had T2 and 2 had T3 in WIACRT (p = NS). In DIACRT, the treatment schedule consisted of intra-arterial chemotherapy (DOC, total 60 mg/m2; CDDP, total 150 mg/m2) and daily concurrent radiotherapy (RT) (total, 60 Gy). In WIACRT, the treatment schedule consisted of intra-arterial chemotherapy (CDDP, total 360 mg/m2) and daily concurrent RT (total, 60 Gy). Results: The median follow-up periods for DIACRT and WIACRT were 61 and 66 months respectively. The 5-year local control (LC) and overall survival (OS) rate were 94.5% and 89.6% for DIACRT group, 60.6% and 63.6% for WIACRT group respectively. The LC rate and OS of DIACRT group were significantly higher than that of WIACRT group. As regards toxicities, no treatment-related deaths were observed during the follow-up periods both in two groups. Conclusions: DIACRT was found to be feasible and effective for patients with tongue cancer and could become a new treatment modality.

Keywords

oral cancer; radiotherapy; intra-arterial chemotherapy; head and neck cancer

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.